Drug intelligence / Profile preview

PXS-2200

Development stage: Preclinical
Lead developer: Syntara
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics

Overview

PXS-2200 is an antisense oligonucleotide (ASO) drug candidate developed by Syntara. It is being investigated for immune system and respiratory diseases, with asthma as a primary indication. The precise molecular target and mechanism of action have not been disclosed in public sources as of June 2025. The drug remains in the discovery or preclinical stage, with no clinical trial results or regulatory approvals reported[1][4].

Beyond the preview

Go deeper on PXS-2200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PXS-2200.

Explore the full profile